STUDY PURPOSE:

The purpose of this research study is to learn more about REMTERNETUG, a possible new medicine for the treatment of early Alzheimer’s disease (AD).  About 1200 people will be in this study.

STUDY DURATION:

This study will take about 5 years to complete.

STUDY COMMITMENT:

PRE-SCREENING AND SCREENING PERIOD: About 21 weeks or 5 months.

TREATMENT PERIOD: About 78 weeks

OBSERVATION PERIOD: About 2-3 years, but may be extended.

FOLLOW UP PERIOD: Up to 20 weeks (1 visit)

To be enrolled in this study, you must meet certain requirements. You may be eligible to participate if you meet the following criteria:

CONDITIONS/ELIGIBILITY:

OVERVIEW OF EXCLUSIONARY CRITERIA: 

Not between the ages of 55 and 80 years old.                  

Prior diagnosis of dementia or other neurological disease documented in their medical record and/or diagnosed by a physician. 

Are currently enrolled in any other medical research (interventional or observational) judged not to be scientifically or medically compatible with this study.  

Have received active immunization against Amyloid Beta in any other study.  

STUDY PROCEDURES:

• Blood draws and urine collection for laboratory tests.
• Electrocardiogram (ECG).
• Magnetic-resonance imaging (MRI).
• Questionnaires related to the study (some with recordings of your audio and video).

COMPENSATION:

Both Participant and Study Partner will be compensated for their participation in this clinical trial.